[Comparison of early bone histomorphometric effects of parathormone and alendronate in osteoporotic women].
Alendronate and teparatide, recombinant human PTH (1-34) are available treatment for osteoporosis in postmenopausal women. They act through opposite mechanisms of action. Alendronate reduces the remodeling of bone and thus increases secondary mineralization without any change in the amount of bone. Teriparatide, 20 micrograms/day, a bone forming agent would increase the amount of bone through two mechanisms, modeling--formation without resorption, and remodeling--resorption then formation with formation higher than resorption. Theses effects are present at the sixth month.
Arlot
Monique
M
INSERM U 403, Laboratoire d'histodynamique Faculté Laennec Rue Paradin F-69008 Lyon. arlot@laennec.univ-lyon1.fr
Roux
Jean-Paul
JP
Portero
Nathalie
N
Boivin
Georges
G
Meunier
Pierre J
PJ
D019386:Alendronate / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology*; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D019379:Teriparatide / Q000627:therapeutic use
D010281:Parathyroid Hormone; D019379:Teriparatide; D019386:Alendronate